Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


      © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Clomipramine

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Clomipramine Hcl Manufacturers in India Suppliers Clomipramine Hcl Exporters Distributors Clomipramine Hcl api active pharmaceuticals ingredients Clomipramine Hcl manufacturers Side Effects bulk drugs raw material Clomipramine Hcl companies Side Effects Importers Clomipramine Hcl Clomipramine Hcl Exporters Clomipramine Hcl exporters FDA Clomipramine Hcl DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Clomipramine Hydrochloride manufacturing pharmaceutical drugs pharmaceutical intermediates Clomipramine Hydrochloride pharmaceutical chemicals pharmaceutical raw materials Clomipramine Hydrochloride active pharmaceutical ingredients Clomipramine Hydrochloride committee active pharmaceutical ingredients manufacturer Clomipramine Hydrochloride Active Pharmaceutical Ingredients manufacturer Clomipramine Hydrochloride exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Clomipramine Hcl, Clomipramine Hcl manufacturer India, Clomipramine Hcl product, Clomipramine Hcl products, Api preparation, Certificate of Analysis API manufacturer product, Clomipramine Hcl anti ulcer product, Certificate of Origin COA Clomipramine Hcl COS Clomipramine Hcl, pharmaceutical generic, pharmaceutical drug, medical, Clomipramine Hcl pharma healthcare, pharma patents, contract MSDS manufacturing Trader Clomipramine Hcl pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Clomipramine Hcl expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Clomipramine Hcl DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Clomipramine Hcl ingredients, api, HIV Clomipramine Hcl, tablets, capsules, syrup & protein Clomipramine Hcl powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Clomipramine Hcl gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Clomipramine Hcl WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 

Clomipramine










 



























 

 

 

 



 

 

HOME >> API >> API List1 >> Clomipramine HCL >> Pharmalogy

Formula C19H23ClN2


PHARMALOGY
Clomipramine CAS number 17321-77-6

Clomipramine is the 3-chloro derivative of imipramine. Clomipramine is a strong, but not completely selective serotonin reuptake inhibitor (SSRI), as the primary active metabolite desmethylclomipramine acts preferably as norepinephrine reuptake inhibitor. Other hydroxy-metabolites are also active. α1 receptor blockage and β receptor downregulation as well as postsynaptic antagonism on histamine H1 receptors and dopamine receptors have been noted.

As with other tricyclics, downregulation of NMDA receptors may also account for its effects.

Clomipramine has the disadvantage of a higher incidence of seizures than seen with other tricyclic antidepressants (up to a dose of 250 mg daily in 0,5 %, more than 300 mg in 2 %).

Clomipramine is a tricyclic agent with both antidepressant and antiobsessional properties. Like other tricyclics, clomipramine inhibits norepinephrine and serotonin uptake into central nerve terminals, possibly by blocking the membrane-pump of neurons, thereby increasing the concentration of transmitter monoamines at receptor sites. Clomipramine is presumed to influence depression and obsessive and compulsive behaviour through its effects on serotonergic neurotransmission. The actual neurochemical mechanism is unknown, but clomipramine's capacity to inhibit serotonin reuptake is thought to be important. Clomipramine appears to have a mild sedative effect which may be helpful in alleviating the anxiety component often accompanying depression.

As with other tricyclic compounds, clomipramine possesses anticholinergic properties which are responsible for some of its side effects. It also has weak antihistamine and antiserotonin properties, lowers the convulsive threshold, potentiates the effect of norepinephrine and other drugs acting on the CNS, has a quinidine-like effect on the heart and may impair cardiac conduction.

The action of clomipramine on the human EEG is one of desynchronization. It causes a persistent increase in the frequency of shifts into stage I sleep and produces marked reduction or suppression of rapid eye movement sleep (REM or paradoxical sleep) with partial recovery within 3 to 4 weeks and a rebound after drug withdrawal which appears to last approximately the same time. In normal human volunteers tricyclic antidepressants tend to produce a sedative effect accompanied by atropine-like symptoms and may produce some difficulty in concentrating and thinking.

Absorption is rapid and complete after oral administration in man. Plasma levels usually peak 2 hours after dosage but much individual variation occurs. The plasma half-life after a single oral dose is approximately 21 hours. After 28 days of oral administration to patients in a daily dosage of 75 mg, plasma concentrations of clomipramine ranged from 17 to 70 ng/mL (mean=35.7 ng/mL). The concentration of the active metabolite, desmethylclomipramine, was about twice as high.

Binding to serum proteins at 96 to 97% is very high and is practically concentration-independent within the therapeutic range. Clomipramine has a volume of distribution of approximately 12 L/kg bodyweight.

Clomipramine is extensively metabolized in the body with hydroxylation, demethylation and N-oxidation being the quantitatively more important routes of metabolism.

Owing to the lower clearance of clomipramine in plasma, elderly patients require lower doses of clomipramine than patients in younger age groups.

As expected, the metabolites of clomipramine are quite similar to those of imipramine, all retaining the benzazepine structure. Two-thirds of clomipramine is excreted in the form of water-soluble conjugates in the urine and approximately one-third in the feces. After a 25 mg radiolabelled dose of clomipramine in 2 subjects, the urinary recoveries of clomipramine and desmethylclomipramine were about 2% and 0.5% of the total radioactivity, respectively.

Information Associated with Product:
DRUG DESCRIPTION
DOSAGE
SIDE EFFECTS
PRECAUTIONS
INTERACTION
PHARMALOGY >>
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Clomipramine Hcl

Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium

Clonazepam

Amitriptyline

Clopidogrel Bisulfate

Anastrozole

Danazol

Atomoxetine Hcl

Desloratadine

Balsalazide

Desmopressin Monoacetate

Bicalutamide

Divalproex Sodium

Budesonide

Dobutamine Hcl

Bupropion Hcl

Donepezil

Calcitonin

Dothiepin Hcl

Capecitabine

Entacapone

Carbamazepine

Eptifibatide

Carboplatin

Escitalopram HBr

Carisoprodol

Eszopiclone

Carvedilol

Finasteride

Cefuroxime Axetil

Flurbiprofen

Cisplatin

Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.